vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and TPG Mortgage Investment Trust, Inc. (MITT). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $20.4M, roughly 1.8× TPG Mortgage Investment Trust, Inc.). TPG Mortgage Investment Trust, Inc. runs the higher net margin — 65.0% vs -3.7%, a 68.6% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 17.7%). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 9.1%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
TPG Mortgage Investment Trust, Inc. is a real estate investment trust managed by global alternative asset firm TPG. It primarily invests in residential and commercial mortgage-backed securities, performing and non-performing mortgage loans, and other credit-linked real estate assets, with its core market being the United States. It generates returns via net interest income from holdings and strategic asset disposition gains.
GYRE vs MITT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $20.4M |
| Net Profit | $-1.4M | $13.3M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | 67.1% |
| Net Margin | -3.7% | 65.0% |
| Revenue YoY | 33.4% | 17.7% |
| Net Profit YoY | -340.1% | -7.0% |
| EPS (diluted) | $-0.01 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $20.4M | ||
| Q3 25 | $30.6M | $19.5M | ||
| Q2 25 | $26.8M | $17.8M | ||
| Q1 25 | $22.1M | $18.8M | ||
| Q4 24 | $27.9M | $17.4M | ||
| Q3 24 | $25.5M | $14.9M | ||
| Q2 24 | $25.2M | $16.4M | ||
| Q1 24 | $27.2M | $17.2M |
| Q4 25 | $-1.4M | $13.3M | ||
| Q3 25 | $5.9M | $20.0M | ||
| Q2 25 | $1.6M | $3.9M | ||
| Q1 25 | $3.7M | $11.5M | ||
| Q4 24 | $569.0K | $14.3M | ||
| Q3 24 | $2.9M | $16.6M | ||
| Q2 24 | $4.5M | $3.9M | ||
| Q1 24 | $9.9M | $20.9M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | 67.1% | ||
| Q3 25 | 22.7% | — | ||
| Q2 25 | 8.1% | 20.9% | ||
| Q1 25 | 10.3% | 54.6% | ||
| Q4 24 | 2.4% | 76.7% | ||
| Q3 24 | 16.6% | — | ||
| Q2 24 | 12.7% | 18.4% | ||
| Q1 24 | 29.7% | — |
| Q4 25 | -3.7% | 65.0% | ||
| Q3 25 | 19.4% | 102.5% | ||
| Q2 25 | 5.9% | 22.2% | ||
| Q1 25 | 16.9% | 60.9% | ||
| Q4 24 | 2.0% | 82.2% | ||
| Q3 24 | 11.2% | 111.3% | ||
| Q2 24 | 18.0% | 24.0% | ||
| Q1 24 | 36.6% | 121.6% |
| Q4 25 | $-0.01 | $0.27 | ||
| Q3 25 | $0.03 | $0.47 | ||
| Q2 25 | $0.00 | $-0.05 | ||
| Q1 25 | $0.00 | $0.21 | ||
| Q4 24 | $0.00 | $0.30 | ||
| Q3 24 | $0.01 | $0.40 | ||
| Q2 24 | $0.01 | $-0.02 | ||
| Q1 24 | $0.03 | $0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $57.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.0M | $560.7M |
| Total Assets | $166.1M | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $57.8M | ||
| Q3 25 | $60.0M | $59.0M | ||
| Q2 25 | $54.4M | $88.7M | ||
| Q1 25 | $29.9M | $115.5M | ||
| Q4 24 | $26.7M | $118.7M | ||
| Q3 24 | $25.1M | $102.5M | ||
| Q2 24 | $25.1M | $120.9M | ||
| Q1 24 | $37.4M | $100.3M |
| Q4 25 | $106.0M | $560.7M | ||
| Q3 25 | $101.9M | $559.8M | ||
| Q2 25 | $92.0M | $536.4M | ||
| Q1 25 | $68.1M | $543.9M | ||
| Q4 24 | $63.3M | $543.4M | ||
| Q3 24 | $63.2M | $540.1M | ||
| Q2 24 | $60.4M | $533.5M | ||
| Q1 24 | $56.6M | $539.6M |
| Q4 25 | $166.1M | $8.7B | ||
| Q3 25 | $159.4M | $9.0B | ||
| Q2 25 | $152.6M | $7.5B | ||
| Q1 25 | $129.8M | $7.3B | ||
| Q4 24 | $125.4M | $6.9B | ||
| Q3 24 | $125.2M | $7.0B | ||
| Q2 24 | $120.9M | $7.1B | ||
| Q1 24 | $122.0M | $6.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $59.6M |
| Free Cash FlowOCF − Capex | $-5.8M | — |
| FCF MarginFCF / Revenue | -15.5% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | 4.48× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $59.6M | ||
| Q3 25 | $4.7M | $17.4M | ||
| Q2 25 | $2.1M | $11.5M | ||
| Q1 25 | $-129.0K | $12.0M | ||
| Q4 24 | $-2.8M | $55.8M | ||
| Q3 24 | $1.7M | $14.5M | ||
| Q2 24 | $-5.5M | $13.7M | ||
| Q1 24 | $2.9M | $12.0M |
| Q4 25 | $-5.8M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $-251.0K | — | ||
| Q4 24 | $-2.8M | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $-6.9M | — | ||
| Q1 24 | $2.7M | — |
| Q4 25 | -15.5% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | -1.1% | — | ||
| Q4 24 | -10.1% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | -27.5% | — | ||
| Q1 24 | 9.8% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | — | 4.48× | ||
| Q3 25 | 0.79× | 0.87× | ||
| Q2 25 | 1.32× | 2.92× | ||
| Q1 25 | -0.03× | 1.05× | ||
| Q4 24 | -4.85× | 3.91× | ||
| Q3 24 | 0.60× | 0.87× | ||
| Q2 24 | -1.21× | 3.50× | ||
| Q1 24 | 0.29× | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
